[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-cancer-hepatocellular-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-cancer-hepatocellular-carcinoma":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100614786","a-study-to-evaluate-patient-reported-satisfaction-effectiveness-and-safety-of-atezolizumab-in-participants-treated-in-routine-clinical-practice-100614786",false,"NCT07284121","A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice","A Non-Interventional, Multicenter, Multicohort Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Subcutaneous Atezolizumab in Participants Treated in Routine Clinical Practice","Inclusion Criteria:\n\n* Participants must have one of the following confirmed diagnoses for which atezolizumab is approved in the local SmPC:\n\n  * Early stage NSCLC following complete resection and platinum-based chemotherapy with a high risk of recurrence and PD-L1 expression on ≥ 50% of TC and with no EGFR-mutant or ALK-positive NSCLC\n  * Metastatic stage NSCLC with PD-L1 expression on ≥ 50% TC or ≥ 10% tumor infiltrating immune cells (IC) and with no EGFR-mutant or ALK-positive NSCLC not previously treated\n  * Extensive-stage small cell lung cancer (ES-SCLC) not previously treated\n  * Advanced or unresectable HCC not previously treated with systemic therapy\n* Should not have received \\> 4 prior cycles of IV Atezolizumab\n\nExclusion Criteria:\n\n* Not receiving treatment with Atezolizumab according to standard of care and in line with the current SmPC or local labelling\n* Receiving concomitant systemic anticancer therapy at the time of initiation of Atezolizumab or an Atezolizumab-containing regimen for treatment of the same disease, as per label\n* Receiving treatment with Atezolizumab as part of a clinical trial, pre-approval access program, compassionate use program, expanded use program, post-trial access program, or continued access program\n* Unwilling to complete questionnaires related to treatment satisfaction and treatment-related quality of life","ALL","18 Years",{"count":19,"type":20},700,"ESTIMATED","OBSERVATIONAL","This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.",[24],"Lung Cancer, Hepatocellular Carcinoma","RECRUITING","2026-08-13",{"date":28,"type":29},"2026-08-17","ACTUAL",{"date":31,"type":29},"2025-07-15",{"date":33,"type":20},"2028-12-31",{"name":35,"class":36},"Hoffmann-La Roche","INDUSTRY",91]